Combination pharmaceutical agents as RSV inhibitors

A method of treating a human respiratory syncytial virus infection in a subject in need thereof, comprising administering to the subject a compound represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is selected from the group consisting of:
• 1) Hydrogen;
• 2) Halogen;
• 3) CN;
• 4) Optionally substituted —C1-C8 alkyl;
• and
• 5) Optionally substituted —C1-C8 alkyl —O—R11;
• R2 and R5 are each independently selected from the group consisting of:
• 1) Hydrogen;
• and
• 2) Optionally substituted —C1-C8 alkyl;
• A is selected from the group below:
• R3 is hydrogen or R11;
• R4 is selected from the group consisting of:
• 1) Optionally substituted —C3-C12 cycloalkyl;
• 2) Optionally substituted —C3-C12 cycloalkenyl;
• 3) Optionally substituted 3- to 12-membered heterocyclyl;
• 4) Optionally substituted aryl;
• 5) Optionally substituted heteroaryl;
• 6) Optionally substituted aryl-O—;
• 7) Optionally substituted heteroaryl-O;
• 8) Optionally substituted aryl-C1-C4-alkyl;
• and
• 9) Optionally substituted heteroaryl-C1-C4-alkyl;
• each R6 is the same or different and independently selected from hydrogen, halogen, hydroxyl, protected hydroxyl, cyano, amino, protected amino, nitro, optionally substituted —C1-C8 alkyl, optionally substituted —C1-C8 alkoxy, optionally substituted —NHC1-C8 alkyl, optionally substituted —S—(—C1-C8 alkyl), optionally substituted —SO2—(—C1-C8 alkyl), — optionally substituted —SO2—NH—(—C1-C8 alkyl), optionally substituted —NH—SO2—(—C1-C8 alkyl), —CO2R12, —NR13R14, and —CO—NR13R14;
• R11 and R12 are each independently is selected from the group consisting of:
• 1) Optionally substituted —C1-C8 alkyl;
• 2) Optionally substituted —C2-C8 alkenyl;
• 3) Optionally substituted —C2-C8 alkynyl;
• 4) Optionally substituted —C3-C8 cycloalkyl;
• 5) Optionally substituted —C3-C8 cycloalkenyl;
• 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
• 7) Optionally substituted aryl;
• and
• 8) Optionally substituted heteroaryl;
• R13 and R14 are each independently selected from hydrogen, optionally substituted —C1-C8—alkyl, optionally substituted —C2-C8-alkenyl, optionally substituted —C2-C8-alkynyl;
• optionally substituted —C3-C8-cycloalkyl, —C(O)R12, —S(O)2R12, and —S(O)2NHR12, and optionally substituted —C1-C8-alkoxy;
• alternatively, R13 and R14 are taken together with the nitrogen they attached to form a heterocyclic ring;
• and n is 0, 1, 2, 3 or 4;
• and a second anti-respiratory syncytial virus agent,
• wherein the compound of Formula I and the second agent are administered in a combined amount which is therapeutically effective.